FDA Oncology Announcements

TGF-beta inhibitor × Clear all

3 Announcements

FDA approves luspatercept-aamt for anemia in adults with MDS

Drug: REBLOZYL (luspatercept-aamt) · TGF-beta inhibitor
Conditions: Classical hematologyMyeloid

FDA approves luspatercept-aamt for anemia in adults with MDS

Trial: MEDALIST
Drug: REBLOZYL (luspatercept-aamt) · TGF-beta inhibitor
Conditions: Classical hematologyMyeloid

FDA approves luspatercept-aamt for anemia in patients with beta thalassemia

Trial: BELIEVE
Drug: REBLOZYL (luspatercept-aamt) · TGF-beta inhibitor
Condition: Classical hematology